NPPA fixes retail price of Glenmark Vildagliptin, Metformin combo drug at Rs 6.17 per tablet

Published On 2020-09-01 08:56 GMT   |   Update On 2020-09-01 08:56 GMT

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has recently fixed the price of popular combination formulation, Vildagliptin + Metformin HCL Tablet manufactured by Glenmark Pharmaceuticals Ltd. at Rs 6.17 per tablet.Each film-coated tablet of the formulation- Vildagliptin + Metformin HCL Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 500mg. The drug is...

Login or Register to read the full article

New Delhi: The National Pharmaceutical Pricing Authority (NPPA) has recently fixed the price of popular combination formulation, Vildagliptin + Metformin HCL Tablet manufactured by Glenmark Pharmaceuticals Ltd. at Rs 6.17 per tablet.

Each film-coated tablet of the formulation- Vildagliptin + Metformin HCL Tablet contains Vildagliptin 50mg, Metformin Hydrochloride IP 500mg. The drug is identified to treat type 2 diabetes mellitus and is sold in the market by various manufactures under different brand names.

The product manufactured by Glenmark also got its price fixed by NPPA as the notification read;

In exercise of the powers conferred by paragraphs 5, 11, and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 701(E) dated 10th March 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Sl.

No.

Name of the Formulation /

Brand Name

Strength

Unit

Manufacturer & Marketing Company

Retail Price

(Rs.)

(1)

(2)

(3)

(4)

(5)

(6)

1.

Vildagliptin +

Each film-coated tablet

1 Tablet

M/s Exemed

6.17

Metformin HCL

contains:

Pharmaceuticals / M/s

Tablet

Vildagliptin 50mg,

Glenmark

Metformin Hydrochloride IP

Pharmaceuticals

500mg

Limited

The notice further added;

(a) The manufacturer of the above-mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.

(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.

(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS, and submit a copy to State Drug Controller and dealers.

(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.

(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

For more details click on the link below-

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News